Abstract
MOTS CLES Denervation renale ; Hypertension ; Ablation ; Renal denervation for the treatment of resistant hypertension has prompted tremendous interest in the medical community, from hypertension specialists to interventional cardiologists. At the end of 2010, the amazing results of the Symplicity HTN-1 and -2 trials, showing a huge reduction in office blood pressure (BP) in patients with uncontrolled hypertension despite treatment with more than five medications on average, led many physicians to ‘dream’ that this non-pharmacological technique could be used in the future in less severe hypertension [1,2]. The ‘market’ is potentially huge, and many companies set up their own devices to perform renal denervation; numerous meetings and symposia were held, and many interventional cardiologists were ready to ‘denervate’ arteries. Everyone predicted a rapid rise in the number of patients treated with this technique. But, three years later, not as many patients as anticipated have been treated, at least not in France. This was probably due to economic considerations because the device was not reimbursed, but also to the position of
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
